Search

Displaying results 4691 - 4700 of 9333 in total
  1. Drug

    NTLA-2002

    go.drugbank.com/drugs/DB17597
    Investigational

    It is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.[L45738] … NTLA-2002 is a lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9.

    Synonyms: lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9
  2. Drug

    Melitracen

    go.drugbank.com/drugs/DB13384
    Investigational

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Imipramine oxide

    go.drugbank.com/drugs/DB13782
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    Lofepramine

    go.drugbank.com/drugs/DB13411
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  5. Drug

    Dihydroetorphine

    go.drugbank.com/drugs/DB01450
    ExperimentalIllicit

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    DYN-101

    go.drugbank.com/drugs/DB17921
    Investigational

    DYN-101 is an antisense product candidate designed to reduce the expression of dynamin 2 protein.

  7. Drug

    Thallium Tl-201

    go.drugbank.com/drugs/DB15361
    Investigational

    Thallium Tl-201 is under investigation in clinical trial NCT02697760 (The CZT Dynamic Myocardial Perfusion Imaging).

    Synonyms: Thallium Tl-201
  8. Drug

    Clorindione

    go.drugbank.com/drugs/DB13275
    Experimental

    Clorindione is a vitamin K antagonist, which may be useful to decrease prothrombin levels in humans.

  9. Drug

    Mebeverine

    go.drugbank.com/drugs/DB12554
    ApprovedInvestigationalWithdrawn

    Mebeverine has been investigated for the treatment of Irritable Bowel Syndrome and Post-cholecystectomy Gastrointestinal Spasms.

    Products: DUSPATALIN CÁPSULA DE LIBERACIÓN PROLONGADA 200 MG., DUSPATALIN® CÁPSULA DE LIBERACIÓN PROLONGADA 200 MG
  10. Drug

    NRP290

    go.drugbank.com/drugs/DB06383
    Experimental

    NRP290 is a hydrocodone derivative under investigation for the treatment of pain (moderate to moderately severe).